A Phase I/II Trial of VB-111 and Paclitaxel for Recurrent Platinum-Resistant Müllerian Cancer
Status:
Completed
Trial end date:
2017-05-03
Target enrollment:
Participant gender:
Summary
This is a prospective, open label, dose escalating, Phase I/II study, measuring mainly the
safety and tolerability of the combination of intravenous administration of VB-111 and
paclitaxel in patients with platinum resistant ovarian cancer.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Vascular Biogenics Ltd. operating as VBL Therapeutics